Screening, Prevention, Etiology, and Cancer Survivorship Program Summary The goal of the SPECS Program is to address the broad spectrum of cancer control, including etiology, prevention, early detection, treatment, and survivorship.
The specific aims of the SPECS Program are to 1) prevent cancer by identifying risk factors and developing novel products and public policies to reduce exposure, 2) detect cancer at an early stage and understand the risks and benefits of diagnosis and treatment options, and 3) identify factors that impact prognosis and quality of life among cancer survivors. The SPECS Program is led by Anne Joseph, MD, MPH; Heather Nelson, MPH, PhD; and Karen Kuntz, ScD and has 49 members, representing 18 departments, 8 schools or colleges, and 4 external organizations. For the last budget year, these members were supported by $2.3 million in direct research funding from the National Cancer Institute; support from all sponsored sources totaled $8.0 million in direct research funding. Since 2013, Program members have published 1564 papers (6% in high-impact journals), 20% of which resulted from intraprogrammatic collaborations, 12% from interprogrammatic collaborations, and 85% from external collaborations. Since 2013, 185 clinical trials in all clinical research categories have opened under this programmatic area and have accrued 13,122 subjects. The Masonic Cancer Center has provided substantial value to the program, including access to shared resources, investment in the recruitment of a new faculty member, funding of 21 pilot projects totaling over $500,000, and 5 research retreats. The SPECS Program research portfolio spans the cancer continuum, including the study of etiology, prevention, early detection, diagnosis, treatment, and survivorship. Crosscutting themes include communication, health disparities, health promotion, biomarkers, epidemiology, decision modeling and cost-effectiveness analysis, and public policy. SPECS research is directed at the cancer burdens of the diverse populations of Minnesota, including the needs of new immigrant, Native American, and other vulnerable populations. SPECS researcher has particular focus on cervical, colon, lung, and prostate cancers, mirroring the disease incidences of our populations. SPECS investigators make excellent use of Masonic Cancer Center Shared Resources, especially Analytical Biochemistry, Biostatistics, and Clinical Informatics. There is an active training component, including T32s on cancer and health disparities, pediatric cancer epidemiology, and health services research. SPECS directly addresses several Scientific Priorities for Growth (SPG) including, SPG4 ? use biomarkers to individualize cancer prevention, SPG5 ? Establish a new Minnesota-based cohort, and SPG6 ? Develop effective methods to increase adoption of evidence-based cancer prevention behaviors by vulnerable populations with disproportionate cancer burden in Minnesota.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-23
Application #
10086451
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1998-06-01
Project End
2024-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
23
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Ma, Bin; Zarth, Adam T; Carlson, Erik S et al. (2018) Methyl DNA Phosphate Adduct Formation in Rats Treated Chronically with 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and Enantiomers of Its Metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol 31:48-57
Hatsukami, Dorothy K; Luo, Xianghua; Jensen, Joni A et al. (2018) Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. JAMA 320:880-891
Lee, Hak Rae; Leslie, Faith; Azarin, Samira M (2018) A facile in vitro platform to study cancer cell dormancy under hypoxic microenvironments using CoCl2. J Biol Eng 12:12
Yang, Libang; Herrera, Jeremy; Gilbertsen, Adam et al. (2018) IL-8 mediates idiopathic pulmonary fibrosis mesenchymal progenitor cell fibrogenicity. Am J Physiol Lung Cell Mol Physiol 314:L127-L136
Regan Anderson, Tarah M; Ma, Shihong; Perez Kerkvliet, Carlos et al. (2018) Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis. Mol Cancer Res 16:1761-1772
Grzywacz, Bartosz; Moench, Laura; McKenna Jr, David et al. (2018) Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. J Immunother :
Santiago, Victor; Lazaryan, Aleksandr; McClune, Brian et al. (2018) Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome. Leuk Lymphoma 59:958-966
Guo, Jingshu; Villalta, Peter W; Weight, Christopher J et al. (2018) Targeted and Untargeted Detection of DNA Adducts of Aromatic Amine Carcinogens in Human Bladder by Ultra-Performance Liquid Chromatography-High-Resolution Mass Spectrometry. Chem Res Toxicol :
Boatman, Jeffrey A; Vock, David M; Koopmeiners, Joseph S et al. (2018) Estimating causal effects from a randomized clinical trial when noncompliance is measured with error. Biostatistics 19:103-118
Rashidi, Armin; Shanley, Ryan; Yohe, Sophia L et al. (2018) Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples. Br J Haematol 182:887-894

Showing the most recent 10 out of 1013 publications